Previous 10 | Next 10 |
Gainers: NuCana NCNA +24%, GeoVax Labs (NASDAQ:GOVX) +11%, NanoVibronix (NASDAQ:NAOV) +9%, Regencell Bioscience (NASDAQ:RGC) +11%, Petros Pharmaceuticals (NASDAQ:PTPI) +7%. Losers: Editas Medicine EDIT -15%, Annexon (NASDAQ:ANNX) -15%, Happine...
Applied UV AUVI +41% on KES Science & Technology assets acquisition GeoVax Labs GOVX +24% after deal for clinical-stage cancer program NuCana (NASDAQ:NCNA) +15% receives fast track designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031...
EDINBURGH, United Kingdom, Sept. 29, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin (NUC-1031), currently being evaluated in a Phase III study (NuTide:121) for the first-line treatm...
NUC-3373 Continues to Demonstrate Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer NUC-3373 Phase 1 Study Demonstrated Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Solid Tumors ...
Enrollment of 418 Evaluable Patients Expected to Enable First Interim Analysis in the First Half of 2022 Data from First Interim Analysis May Support an NDA Submission in the United States under the FDA’s Accelerated Approval Program EDINBURGH, United Kingdom, Sept....
The market continues to overlook NuCana and its fascinating ProTide platform technology, which could spawn a manifold of drugs that may outclass the existing standard of care products. The share price continues to be under pressure and has allowed me to enter NCNA at an attractive ris...
EDINBURGH, United Kingdom, Aug. 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics. As of June 30, 2021, NuCana ...
EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be...
NuCana plc (NASDAQ:NCNA) traded at a new 52-week low today of $2.20. Approximately 461,000 shares have changed hands today, as compared to an average 30-day volume of 822,000 shares. NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by P...
NuCana plc (NASDAQ:NCNA) traded today at a new 52-week low of $2.40. Approximately 461,000 shares have changed hands today, as compared to an average 30-day volume of 988,000 shares. NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by P...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...